MicroRNA193a: An Emerging Mediator of Glomerular Diseases

Area of Science:

• Molecular Biology
• Nephrology
• Biomarker Discovery

Background:

• MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression, with potential as disease biomarkers.
• MiR-193a has been implicated in focal segmental glomerulosclerosis (FSGS) pathogenesis, downregulating Wilm's tumor-1 (WT-1) and influencing podocyte phenotype.
• Emerging evidence suggests miR-193a's involvement in other glomerular diseases, including diabetic nephropathy and membranous nephropathy.

Purpose of the Study:

• To review the pathogenic mechanisms of miR-193a elevation in various glomerular diseases.
• To explore the potential of miR-193a as a clinical management biomarker for FSGS and diabetic nephropathy.
• To highlight the need for further research into the causes and differential mechanisms of miR-193a upregulation in glomerular disorders.

Main Methods:

• Literature review of studies investigating miR-193a in glomerular diseases.
• Analysis of experimental and in vitro data on miR-193a's molecular targets and functions.
• Synthesis of current understanding regarding miR-193a's role in FSGS, diabetic nephropathy, and membranous nephropathy.

Main Results:

• MiR-193a directly impacts FSGS pathology by downregulating WT-1 and promoting podocyte transdifferentiation.
• Potential interaction of miR-193a with apolipoprotein 1 (APOL1) mRNA suggests a role in common glomerular disease pathogenesis.
• Increasing interest in miR-193a's role across diverse glomerular conditions beyond FSGS.

Conclusions:

• MiR-193a is a significant factor in glomerular disease pathogenesis, particularly FSGS.
• Understanding miR-193a upregulation mechanisms is crucial for developing novel biomarkers and therapeutic strategies.
• Further investigation is warranted to elucidate miR-193a's specific roles and clinical utility in managing kidney diseases.